FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293493989> ?p ?o ?g. }

• W4293493989 endingPage "1198" @default.
• W4293493989 startingPage "1184" @default.
• W4293493989 abstract "Drug resistance has greatly limited the clinical efficacy of lenvatinib in hepatocellular carcinoma (HCC). However, the underlying molecular mechanisms of lenvatinib resistance remain largely undetermined. Further in-depth exploration of mechanisms underlying lenvatinib resistance is still required for the majority of HCC patients. In this study, an integrated unbiased whole-genome CRISPR-Cas9 screen with database analysis indicated LAPTM5 (lysosomal protein transmembrane 5) as the critical contributor to lenvatinib resistance in HCC. We revealed that LAPTM5 could promote intrinsic macroautophagic/autophagic flux by facilitating autolysosome formation to drive lenvatinib resistance. The upregulation of LAPTM5 in HCC was induced by both DNA hypomethylation and driver mutations like TP53. Inhibition of autolysosome formation by either hydroxychloroquine (HCQ) or LAPTM5 abrogation worked synergistically with lenvatinib to inhibit tumor growth. In HCC cell lines, patient-derived primary cell lines and organoids, as well as human HCC xenografts and immunocompetent mouse HCC model, the close association between LAPTM5 and sensitivity to lenvatinib was consistently verified. Importantly, in clinical HCC samples, where lenvatinib was used as the first line or adjuvant therapy, LAPTM5 expression negatively correlated with lenvatinib sensitivity, implying it as a biomarker to predict patient response to lenvatinib. In conclusion, the combinational therapy targeting autophagy represented a promising strategy to overcome lenvatinib resistance in HCC, and LAPTM5 expression could provide potential guidance for clinical interference.Abbreviations cld-CASP3: cleaved caspase 3; cld-PARP: cleaved PARP; DTP: drug tolerant persister; GO: Gene Ontology; GTEx: The Genotype-Tissue Expression; HCC: hepatocellular carcinoma; HCQ: hydroxychloroquine; IC50: half maximal inhibitory concentration value; KEGG: Kyoto Encyclopedia of Genes and Genomes; LAPTM5: lysosomal protein transmembrane 5; NT: non-targeting; PDC: patient-derived primary cell lines; PDO: patient-derived primary organoid; TCGA: The Cancer Genome Atlas." @default.
• W4293493989 created "2022-08-29" @default.
• W4293493989 creator A5001372513 @default.
• W4293493989 creator A5015071376 @default.
• W4293493989 creator A5021073603 @default.
• W4293493989 creator A5026977205 @default.
• W4293493989 creator A5029363724 @default.
• W4293493989 creator A5029634246 @default.
• W4293493989 creator A5031371726 @default.
• W4293493989 creator A5044102273 @default.
• W4293493989 creator A5045703368 @default.
• W4293493989 creator A5067302803 @default.
• W4293493989 creator A5077339255 @default.
• W4293493989 creator A5084939652 @default.
• W4293493989 creator A5086674805 @default.
• W4293493989 creator A5088503683 @default.
• W4293493989 date "2022-09-07" @default.
• W4293493989 modified "2023-10-18" @default.
• W4293493989 title "Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma" @default.
• W4293493989 cites W1971837077 @default.
• W4293493989 cites W1973015868 @default.
• W4293493989 cites W1973260880 @default.
• W4293493989 cites W1994193851 @default.
• W4293493989 cites W2019294726 @default.
• W4293493989 cites W2026592619 @default.
• W4293493989 cites W2031211461 @default.
• W4293493989 cites W2032600439 @default.
• W4293493989 cites W2043398720 @default.
• W4293493989 cites W2051193106 @default.
• W4293493989 cites W2064815984 @default.
• W4293493989 cites W2086853865 @default.
• W4293493989 cites W2096198457 @default.
• W4293493989 cites W2100122648 @default.
• W4293493989 cites W2106391833 @default.
• W4293493989 cites W2110643890 @default.
• W4293493989 cites W2275679174 @default.
• W4293493989 cites W2342536142 @default.
• W4293493989 cites W2418831513 @default.
• W4293493989 cites W2560499218 @default.
• W4293493989 cites W2560755435 @default.
• W4293493989 cites W2622649668 @default.
• W4293493989 cites W2771057425 @default.
• W4293493989 cites W2772927056 @default.
• W4293493989 cites W2787358630 @default.
• W4293493989 cites W2790327509 @default.
• W4293493989 cites W2909420934 @default.
• W4293493989 cites W2922081884 @default.
• W4293493989 cites W2927225477 @default.
• W4293493989 cites W2983388001 @default.
• W4293493989 cites W2996358113 @default.
• W4293493989 cites W3000125713 @default.
• W4293493989 cites W3011857315 @default.
• W4293493989 cites W3053923004 @default.
• W4293493989 cites W3098767390 @default.
• W4293493989 cites W3165017392 @default.
• W4293493989 cites W3167009660 @default.
• W4293493989 cites W3183709015 @default.
• W4293493989 cites W3212440187 @default.
• W4293493989 cites W4200105407 @default.
• W4293493989 cites W4211183069 @default.
• W4293493989 cites W4232620598 @default.
• W4293493989 doi "https://doi.org/10.1080/15548627.2022.2117893" @default.
• W4293493989 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36037300" @default.
• W4293493989 hasPublicationYear "2022" @default.
• W4293493989 type Work @default.
• W4293493989 citedByCount "9" @default.
• W4293493989 countsByYear W42934939892023 @default.
• W4293493989 crossrefType "journal-article" @default.
• W4293493989 hasAuthorship W4293493989A5001372513 @default.
• W4293493989 hasAuthorship W4293493989A5015071376 @default.
• W4293493989 hasAuthorship W4293493989A5021073603 @default.
• W4293493989 hasAuthorship W4293493989A5026977205 @default.
• W4293493989 hasAuthorship W4293493989A5029363724 @default.
• W4293493989 hasAuthorship W4293493989A5029634246 @default.
• W4293493989 hasAuthorship W4293493989A5031371726 @default.
• W4293493989 hasAuthorship W4293493989A5044102273 @default.
• W4293493989 hasAuthorship W4293493989A5045703368 @default.
• W4293493989 hasAuthorship W4293493989A5067302803 @default.
• W4293493989 hasAuthorship W4293493989A5077339255 @default.
• W4293493989 hasAuthorship W4293493989A5084939652 @default.
• W4293493989 hasAuthorship W4293493989A5086674805 @default.
• W4293493989 hasAuthorship W4293493989A5088503683 @default.
• W4293493989 hasBestOaLocation W42934939892 @default.
• W4293493989 hasConcept C2776264508 @default.
• W4293493989 hasConcept C2778019345 @default.
• W4293493989 hasConcept C2778695046 @default.
• W4293493989 hasConcept C502942594 @default.
• W4293493989 hasConcept C86803240 @default.
• W4293493989 hasConceptScore W4293493989C2776264508 @default.
• W4293493989 hasConceptScore W4293493989C2778019345 @default.
• W4293493989 hasConceptScore W4293493989C2778695046 @default.
• W4293493989 hasConceptScore W4293493989C502942594 @default.
• W4293493989 hasConceptScore W4293493989C86803240 @default.
• W4293493989 hasFunder F4320321001 @default.
• W4293493989 hasFunder F4320321885 @default.
• W4293493989 hasIssue "4" @default.
• W4293493989 hasLocation W42934939891 @default.
• W4293493989 hasLocation W42934939892 @default.

• next